Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients

Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients

Abstract Background The current standard treatment for neovascular age-related macular degeneration (nAMD) involves intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents. The aim of the present study was to compare the effectiveness and safety of two anti-VEGF drugs:...

Full description

Bibliographic Details
Main Authors: Sanjay Kumar Mishra, Pradeep Kumar, Srishti Khullar, Amrita Joshi, Alok Sati, Sonali Vinay Kumar, Deepesh Unni, Atul Kumar
Format: Article
Language:English
Published: BMC 2022-07-01
Series:International Journal of Retina and Vitreous
Subjects:
Neovascular age-related macular degeneration
nAMD
Brolucizumab
Aflibercept
VEGF
Indian
Online Access:https://doi.org/10.1186/s40942-022-00401-4

Internet

https://doi.org/10.1186/s40942-022-00401-4

Similar Items